Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Fresh from the Pipeline
  • Published:

Sunitinib maleate

Nature Reviews Drug Discovery volume 5, pages 279–280 (2006)Cite this article

Abstract

Sunitinib maleate (Sutent; Pfizer) is a small-molecule inhibitor of multiple receptor tyrosine kinases involved in cancer, including vascular endothelial growth factor receptors, platelet-derived growth factor receptors and the KIT receptor. It was approved by the US FDA for the treatment of gastrointestinal stromal tumours and advanced renal-cell carcinoma in January 2006.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Sunitinib.

References

  1. Krause, D. S. & Van Ettten, R. A. Tyrosine kinases as targets for cancer therapy. N. Engl. J. Med. 353, 172–187 (2005).

    Article  CAS  Google Scholar 

  2. Cohen, H. T. & McGovern, F. J. Renal-cell carcinoma. N. Engl. J. Med. 353, 2477–2490 (2005).

    Article  CAS  Google Scholar 

  3. Atkins, M. B. et al. Innovations and challenges in renal cancer: consensus statement from the first international conference. Clin.Cancer Res. 9, 6277S–6281S (2004).

    Google Scholar 

  4. Bergers, G. et al. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J. Clin. Invest. 111, 1287–1295 (2003).

    Article  CAS  Google Scholar 

  5. Sun, L. et al. Discovery of 5-[5-fluoro-2-oxo-1,2- dihydroindol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel tyrosine kinase inhibitor targeting vascular endothelial and platelet-derived growth factor receptor tyrosine kinase. J. Med. Chem. 46, 1116–1119 (2003).

    Article  CAS  Google Scholar 

  6. Mendel, D. B. et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors. Clin. Cancer Res. 9, 327–337 (2003).

    CAS  PubMed  Google Scholar 

  7. Demetri, G. D. Identification and treatment of chemoresistant inoperable or metastatic GIST: experience with the selective tyrosine kinase inhibitor imatinib mesylate. Eur. J. Cancer 38, S52– S59 (2002).

    Article  Google Scholar 

  8. FDA labelling information [online], (2006).

  9. Motzer, R. J. et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 24, 16–24 (2006).

    Article  CAS  Google Scholar 

  10. Motzer, R. J. et al. Phase 2 trials of SU11248 show antitumor activity in second-line therapy for patients with metastatic renal cell carcinoma (RCC). Proc. Am. Soc. Clin. Oncol. A4508 (2005).

  11. Yang, J. C. et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N. Engl. J. Med. 349, 427–434 (2003).

    Article  CAS  Google Scholar 

  12. Escudier, B. et al. Randomized Phase III trial of the Raf kinase and VEGFR inhibitor sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC). Proc. Am. Soc. Clin. Oncol. A4510 (2005).

  13. Rini, B. et al. AG-013736, a multi-target tyrosine kinase receptor inhibitor, demonstrates anti-tumor activity in a Phase 2 study of cytokine-refractory, metastatic renal cell cancer (RCC). Proc. Am. Soc. Clin. Oncol. A4509 (2005).

Download references

Author information

Authors and Affiliations

  1. the Beth Israel Deaconess Medical Center, 330 Brookline Avenue, KS-158, Boston, 02215, Massachusetts, USA

    Michael Atkins

  2. IMS Health, 7 Harewood Avenue, London, NW1 6JB, UK

    Carole A. Jones

  3. Nature Reviews Drug Discovery,

    Peter Kirkpatrick

Authors
  1. Michael Atkins
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Carole A. Jones
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Peter Kirkpatrick
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Atkins, M., Jones, C. & Kirkpatrick, P. Sunitinib maleate. Nat Rev Drug Discov 5, 279–280 (2006). https://doi.org/10.1038/nrd2012

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd2012

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing